Last reviewed · How we verify
Antitumor B
Antitumor B works by inhibiting cell proliferation and inducing apoptosis in cancer cells.
Antitumor B works by inhibiting cell proliferation and inducing apoptosis in cancer cells. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | Antitumor B |
|---|---|
| Also known as | Zeng Sheng Ping, ATB, ACAPHA |
| Sponsor | Medical College of Wisconsin |
| Drug class | Antitumor agent |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Antitumor B targets and binds to specific molecular pathways involved in cancer cell growth and survival, ultimately leading to the death of cancer cells. This mechanism of action is specific to rapidly dividing cells, making it effective against various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Anemia
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma (PHASE1)
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (PHASE1, PHASE2)
- Inhibition of Oral Tumorigenesis by Antitumor B (EARLY_PHASE1)
- Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. (PHASE1)
- A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors (PHASE1, PHASE2)
- A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (PHASE1)
- A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antitumor B CI brief — competitive landscape report
- Antitumor B updates RSS · CI watch RSS
- Medical College of Wisconsin portfolio CI